TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

So, one of the areas of highest unmet needs in triple-negative breast cancer is the recurrence post-chemo and immunotherapy ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...

Reported net loss was $9.0 million, or $0.19 per basic and diluted share, for the three months ended September 30, 2025, compared to $10.7 million, or $0.29 per basic share and diluted share, for the ...

Patients with advanced melanoma who received fecal microbiota transplants using healthy donor stool alongside standard immunotherapy survived more than four years, according to final results from an ...

MOUNTAINSIDE, NJ - At 97 years old, WWII and Korean War veteran Teddy Grossi faced overwhelming odds. Diagnosed with ...

Now, it’s worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 194% for ...

The U.S. Food and Drug Administration named Richard Pazdur, its longtime overseer of cancer therapies, as its top drug ...

Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of ...